CPT® Code 78016

A nuclear medicine study, specifically CPT® Code 78016, is utilized to assess the presence and extent of metastatic disease related to thyroid carcinoma. This procedure involves the administration of radioactive iodine isotopes, commonly known as radioactive tracers, which can be given either orally in liquid or capsule form or intravenously. The method of administration dictates the timing of the imaging procedure; if the tracer is taken orally, imaging occurs several hours to 24 hours later, allowing sufficient time for the tracer to localize in the tissues. Conversely, if administered intravenously, imaging is conducted approximately 30 minutes post-injection. The radioactive isotopes emit gamma rays, which are captured by a gamma camera. This camera, in conjunction with computer processing, generates images that are displayed on a screen for analysis. In the context of CPT® Code 78016, the imaging focuses on a limited area, typically the neck and chest, to identify any metastatic sites. The gamma camera scans the designated region, tracking the distribution and uptake of the radioactive tracer. If metastatic disease is present, the scanner will reveal how these sites interact with the radioactive material. The resulting gamma images are processed and reviewed by a physician, who then compiles a written report detailing the findings. Additionally, CPT® Code 78016 includes the performance of supplementary studies, such as urinary recovery, to enhance the evaluation of the patient's condition. This procedure is part of a broader diagnostic framework that may also involve whole body surveys, as indicated by related codes such as CPT® Code 78018.